Veloxis is a pharmaceutical company that develops and commercializes therapeutics for organ transplantation and cardiovascular indications... Read more
Veloxis is a pharmaceutical company that develops and commercializes therapeutics for organ transplantation and cardiovascular indications... Read more
President & CEO
Craig A. Collard
News
Apr 28, 2026
Manufacturing Chemist
Veloxis Pharmaceuticals: FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
Apr 27, 2026
MarketScreener
Veloxis Pharmaceuticals: Positive developments for OSE Immunotherapeutics treatment licensed to Veloxis
Apr 20, 2026
FinanzNachrichten
Veloxis Pharmaceuticals: Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
Mar 02, 2026
CEE Legal Matters
Veloxis Pharmaceuticals: Freshfields Advises Veloxis and Asahi Kasei on EUR 780 Million Acquisi
Jan 21, 2026
PR Newswire
Press Release: Veloxis : Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Patients Receiving a Liver Transplant
Jul 30, 2025
StreetInsider
Press Release: Veloxis : Veloxis Pharmaceuticals to Present at 2025 World Transplant Congress
Oct 14, 2022
centralcharts
Press Release: Veloxis : C-Path's Transplant Therapeutics Consortium receives EMA Draft Qualification Opinion for the iBox Scoring System
Sep 19, 2022
Markets Insider
Veloxis: Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation
Jun 28, 2022
FirstWord Pharma
Veloxis: Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
May 18, 2022
FinanzNachrichten
Veloxis: OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
Veloxis Pharmaceuticals Competitors
1
2
3
4
5
6
7
8
9
10